Norepinephrine-dopamine reuptake inhibitor



A norepinephrine-dopamine reuptake inhibitor (NDRI) is a drug that acts as a reuptake inhibitor for the neurotransmitters norepinephrine and dopamine by blocking the action of the norepinephrine transporter (NET) and the dopamine transporter (DAT), respectively. This in turn leads to increased extracellular concentrations of both norepinephrine and dopamine and, therefore, an increase in adrenergic and dopaminergic neurotransmission.

Refer to the directly above-mentioned articles for more information.

Uses
Norepinephrine-dopamine reuptake inhibitors are used for Clinical depression, ADD, ADHD, Narcolepsy, and as antiparkinson agents.

List of NDRIs


Many NDRIs exist, including the following:


 * Amineptine (Survector, Maneon, Directim)
 * Bupropion (Wellbutrin, Zyban)
 * Desoxypipradrol (2-DPMP)
 * Dexmethylphenidate (Focalin)
 * Difemetorex (Cleofil)
 * Diphenylprolinol (D2PM)
 * Fencamfamine (Glucoenergan, Reactivan)
 * Fencamine (Altimina, Sicoclor)
 * Lefetamine (Santenol)
 * Mesocarb (Sidnocarb, Sydnocarb)
 * Methylenedioxypyrovalerone (MDPV)
 * Methylphenidate (Ritalin, Concerta, Metadate, Methylin)
 * Nomifensine (Merital)
 * Pipradrol (Meretran)
 * Prolintane (Promotil, Katovit)
 * Pyrovalerone (Centroton, Thymergix)
 * Tametraline (CP-24,411)

Note: Only NDRIs selective for the NET and DAT over the serotonin transporter (SERT) are listed here. For a list of NDRIs that also act at the SERT, see the SNDRI page.

Additional note: Norepinephrine and dopamine releasing agents (NDRAs) such as psychostimulants of the amphetamine class also act as NDRIs secondarily to their releasing action. To distinguish between NDRIs and NDRAs however, the latter are not included in the above list. For a list of NDRAs, see the releasing agent article.